Article
AZN: Imfinzi Combination Improves Disease-Free Survival In Phase III High-Risk Bladder Cancer Trial
Neutral
0.0
−100 Bearish
0
+100 Bullish
(RTTNews) - AstraZeneca Plc. (AZN, AZN.L) announced that results from the POTOMAC Phase III trial showed that one year of treatment with its Imfinzi (durvalumab), combined with standard Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, significantly improved disea
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
NASDAQ Markets
Published
May 9, 2025 · 6:22 am
Article ID
18455791687381926199
Original URL
Open source
Sentiment Signal
Neutral
0.0
−100Neutral+100
More Like This